EUVIMEDEUVIMED entdecken
Crossref

2191-P: Cardiometabolic–Kidney Staging and Mortality Outcomes in South Asians

RAM JAGANNATHAN, WILHEMINA QUARPONG, DIMPLE KONDAL, KAVITA SINGH, SHIVANI A. PATEL, MOHAN DEEPA, RANJIT MOHAN ANJANA, UNJALI GUJRAL, SAILESH MOHAN, HOWARD H. CHANG, MOHAMMED K. ALI, VISWANATHAN MOHAN und 5 weitere

Diabetes · 05.06.2026 · 75 (Supplement_1)

DOI: 10.2337/db26-2191-p ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes, erschienen am 05.06.2026. Verfasst von RAM JAGANNATHAN und 16 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction and Objective: To examine associations between cardiovascular-kidney-metabolic (CKM) stages and cardiovascular disease (CVD) and all-cause mortality in South Asians, and to evaluate age-specific differences in these risks.

Methods

We analyzed data from 17,430 (51% women; median age 42 y) adults in the cArdiometabolic Risk Reduction in South Asia (CARRS) cohort. We included participants from CARRS-1 (2010-12) and CARRS-2 (2014-16), with a median follow up of 9 y through 2024. CKM stages, based on the 2023 AHA CKM framework, were grouped as 0-1 (optimal/at-risk), 2 (metabolic risk or moderate-to-high risk CKD), and 3-4 (subclinical/clinical CVD or CKD). Cox models with age as the timescale estimated hazard ratios (HRs) for mortality, adjusting for sex, education, income, smoking, and included CKM × age interactions.

Results

At baseline, 59% were in CKM stage 2 and 9% in stages 3-4. Compared with stage 0-1, adjusted HRs (95% CI) for CVD mortality for stage 2 were 2.9 (1.8, 4.9), 2.0 (1.4, 2.9), and 2.4 (1.2, 5.0), and for stages 3-4 were 13.0 (6.4, 26.1), 7.6 (5.3, 10.9), and 4.3 (2.1, 8.7) among those aged <45, 45-64, and ≥65 y, respectively. Similar trends were observed for all-cause mortality (Table).

Conclusion

Advancing CKM stage was associated with progressively higher CVD and all-cause mortality, with the largest relative hazards at younger ages. These findings highlight the deleterious effects of early emergence of CKM in South Asians. Disclosure R. Jagannathan: None. W. Quarpong: None. D. Kondal: None. K. Singh: None. S.A. Patel: None. M. Deepa: None. R. Anjana: None. U. Gujral: None. S. Mohan: None. H.H. Chang: None. M.K. Ali: Consultant; Ended; Eli Lilly and Company, Siemens, Novo Nordisk. V. Mohan: None. A.A. Quyyumi: None. D. Prabhakaran: None. K. Narayan: None. S. Anand: Other - Site PI for VOICE study at US Renal Care; Current; US Renal Care. N. Tandon: None. Funding National Institutes of Health (HHSN2682009900026C; P01HL154996), National Institute on Aging (R01AG89759), National Institute of Diabetes and Digestive and Kidney Diseases (R01DK139632; R21DK105891)

Zitieren

APA

JAGANNATHAN, R., QUARPONG, W., KONDAL, D., SINGH, K., PATEL, S. A., DEEPA, M., ANJANA, R. M., GUJRAL, U., MOHAN, S., CHANG, H. H., ALI, M. K., MOHAN, V., QUYYUMI, A. A., PRABHAKARAN, D., NARAYAN, K. V., ANAND, S., & TANDON, N. (2026). 2191-P: Cardiometabolic–Kidney Staging and Mortality Outcomes in South Asians. Diabetes, 75(Supplement_1). https://doi.org/10.2337/db26-2191-p

Vancouver

JAGANNATHAN R, QUARPONG W, KONDAL D, SINGH K, PATEL SA, DEEPA M, et al. 2191-P: Cardiometabolic–Kidney Staging and Mortality Outcomes in South Asians. Diabetes. 2026;75(Supplement_1). doi:10.2337/db26-2191-p

BibTeX
@article{JAGANNATHAN2026,
  author = {JAGANNATHAN, RAM and QUARPONG, WILHEMINA and KONDAL, DIMPLE and SINGH, KAVITA and PATEL, SHIVANI A. and DEEPA, MOHAN and ANJANA, RANJIT MOHAN and GUJRAL, UNJALI and MOHAN, SAILESH and CHANG, HOWARD H. and ALI, MOHAMMED K. and MOHAN, VISWANATHAN and QUYYUMI, ARSHED A. and PRABHAKARAN, DORAIRAJ and NARAYAN, K.M. VENKAT and ANAND, SHUCHI and TANDON, NIKHIL},
  title = {2191-P: Cardiometabolic–Kidney Staging and Mortality Outcomes in South Asians},
  journal = {Diabetes},
  year = {2026},
  volume = {75},
  number = {Supplement_1},
  doi = {10.2337/db26-2191-p}
}
Kostenlos starten →